The in vitro activity of temocillin (BRL 17421), a new beta-lactamase-stable penicillin, was compared with those of other beta-lactam antibiotics for over 500 clinical bacterial isolates. Temocillin inhibited 94% of the Enterobacteriaceae organisms at concentrations of 0.5 to 8 ,ug/ml, regardless of organism resistance to ampicillin, ticarcillin, cefazolin, or combinations thereof. Most Pseudomonas aeruginosa isolates and all staphylococci and streptococci tested were resistant to temocillin.
Temocillin (BRL 17421) is the 6-a-methoxy derivative of ticarcillin ( Fig. 1) . However, the antibacterial activity as well as the pharmacological properties of both compounds are quite different. The introduction of a methoxy group at the 6-a position of the nucleus confers upon the new drug a high stability against beta-lactamases and broadens the spectrum of its activity against Enterobacteriaceae organisms; however, the new antibiotic completely loses activity against gram-positive organisms and loses most of its activity against Pseudomonas aeruginosa. Temocillin, in addition, is unique among penam antibiotics because of its very prolonged serum half-life (up to 5.5 h) in humans (1) .
In this study, the in vitro activity of temocillin against over 500 clinical isolates was compared with those of ampicillin, ticarcillin, cefazolin, cefuroxime, and moxalactam, a beta-lactam antibiotic also protected against beta-lactamases by a methoxy group. Minimal inhibitory concentrations (MIC) were determined by an agar dilution technique in DST agar (Oxoid Ltd.) with inocula of 10' to 106 colony-forming units (CFU) per spot delivered with a multipoint inoculator.
To support the growth of Haemophilus influenzae and streptococci, I supplemented the DST agar with 5% lysed horse blood. For 12 randomly chosen isolates of Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter spp., and Serratia marcescens, I determined the effect of the inoculum size on the MIC and the minimal bactericidal concentrations (MBC), using inocula of approximately 104, 106 and 108 CFU. The techniques have been described in detail previously (2) .
Temocillin was completely inactive against gram-positive cocci: all five strains of Staphylococcus epidermidis, Streptococcus faecalis, and Streptococcus agalactiae were resistant to a concentration of 512 ,zg/ml. The MIC for five Staphylococcus aureus isolates ranged from 128 to more than 512 ,ug/ml, the MIC for Streptococcus pyogenes ranged from 64 to 128 ,ug/ml, and the MIC for Streptococcus pneumoniae ranged from 128 to 512 ,ug/ml.
The activities of temocillin and the other betalactam antibiotics against 384 Enterobacteriaceae organisms, 73 H. influenzae isolates, and 22 Pseudomonas aeruginosa isolates are shown in Table 1 . In absolute figures, moxalactam was by far the most active of the six antibiotics tested in vitro. Temocillin displayed the same broad spectrum of activity against Enterobacteriaceae organisms as did moxalactam, but the level of activity was not higher than those of ampicillin, ticarcillin, cefazolin, and cefuroxime against species susceptible to these drugs. However, the most prominent feature of temocillin was the short range of the concentrations (generally four) with which all isolates of a species The results of this in vitro study completely confirm the data published by Slocombe and collaborators (1) . The intrinsic activity of temocillin is about the same as those of ampicillin, ticarcillin, cefazolin, and cefuroxime against susceptible organisms, but it is substantially lower than that of moxalactam. However, the difference in in vitro activity between .temocillin and moxalactam may be mitigated by the high and prolonged serum levels of the former in humans (1) . Because temocillin is a derivative of ticarcillin, tolerance or toxicity may not be major obstacles to increasing the dosage.
The very small differences in temocillin MIC between isolates resistant to ampicillin, ticarcillin, cefazolin, or combinations thereof and susceptible isolates, as well as the small effect inoculum size has on temocillin MBC, support the evidence of the high stability of the drug against the wide variety of beta-lactamases present in clinical bacterial isolates highly resistant to the classic beta-lactam antibiotics. In this respect, temocillin is superior to cefuroxime and even slightly superior to moxalactam.
The lack of any activity against anaerobes and gram-positive cocci, including streptococci, may 
